EUCTR2014-001274-34-IT进行中（未招募）1 期
Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant, salivary gland cancers.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed informed consent
- •- Histologically or cytologically confirmed salivary glands cancer.
- •- At least, one target lesion defined as RECIST 1.1 (clear progression of disease is required in the presence of one target lesion previously treated with radiotherapy
- •- Clinical and/or radiological progression of disease on ADT
- •- No limits are required for the number of previous chemotherapy lines
- •- Age =18 years
- •- Eastern Cooperative Oncology Group (ECOG) performance status of =2
- •- Hemoglobin = 9.0 g/dL independent of transfusion
- •- Platelet count = 100,000/µL
- •- Serum albumin = 3.0 g/dL
- •- Serum creatinine <1.5 x upper limit of normal (ULN) or a calculated creatinine clearance = 60 mL/min
- •- Serum potassium =3.5 mmol/L
- •- Able to swallow the study drug whole as a tablet
- •- Patients with treated brain metastases, stable within the last three months, are allowed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •- Received abiraterone acetate within the last 5 years
- •- Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
- •- Abnormal liver functions consisting of any of the following:
- •Serum bilirubin = 1.5 x ULN (except for subjects with documented Gilbert’s disease, for whom the upper limit of serum bilirubin is 3 mg/dL)
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.5 x ULN
- •Patients with ALT and/or AST not exceeding 5X ULN due to liver mets can be enrolled
- •- Uncontrolled hypertension (systolic blood pressure =160 mmHg or diastolic blood pressure =95 mmHg); subjects with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy.
- •- Active or symptomatic viral hepatitis or chronic liver disease
- •- History of pituitary or adrenal dysfunction
- •- Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or left ventricular ejection fraction (LVEF) of <50% at baseline
- •- History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study drug
- •- Any acute toxicities due to prior chemotherapy or radiotherapy that have not resolved to a NCI-CTCAE (Version 4.0) Grade of =1.
- •- Subjects who have partners of childbearing potential who are not willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the investigator and for 13 weeks after last study drug administration
- •- Participation in clinical trials with other experimental agents within 30 days of study entry or concomitant treatment with other experimental drug
- •- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry
研究者
相似试验
已完成
1 期
MAdCaP: MDM2 inhibition and Abiraterone in Carcinoma of the ProstateMalignant neoplasm of prostateCancerProstate cancerISRCTN38949950HS Greater Glasgow and Clyde (UK)132
进行中（未招募）
1 期
A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 in patients with mCRCP who have not previously received docetaxel.CancerEUCTR2013-002014-13-GBHS greater Glasgow and Clyde132
进行中（未招募）
不适用
The study compares the therapy of abiraterone acetate plus LHRH-therapy with the therapy of abiraterone acetate allone in patients with recurrent prostate cancer in spite of chemotherapy and castration, the therapy for every single patient gets select by chanceMedically castrated male patients with chemotherapy-naïve, castration-resistant, metastatic CRPC who have shown tumor progression and are non- or mildly-symptomaticMedDRA version: 16.1Level: LLTClassification code 10066489Term: Progression of prostate cancerSystem Organ Class: 100000004864EUCTR2012-005717-39-DEniversität des Saarlandes
进行中（未招募）
1 期
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentEUCTR2012-004331-23-GBJanssen-Cilag International NV164
进行中（未招募）
1 期
Abiraterone with Different Steroid Medications Regimens for side effect prevention in [metastatic castrate-resistant] prostate cancer patients prior to chemotherapy treatmentMetastatic Castration-Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004331-23-HUJanssen-Cilag International NV144